Hypotef, tablets 50 pcs

Hypotef is a combination drug for the treatment of arterial hypertension in patients over 45 years of age, which has less severe side effects than in monotherapy with its constituent components due to lower doses.

Indications

Arterial hypertension of 1st and 2nd severity in patients over 45 years of age.

Pharmacological effect

Hypotef is a combination drug for the treatment of arterial hypertension in patients over 45 years of age, which has less pronounced side effects than monotherapy with its components due to lower doses.

Special instructions

When used simultaneously with drugs that prolong the QT interval, periodic monitoring of the electrocardiogram is necessary.
The most careful monitoring is indicated in patients with severe heart failure, coronary artery disease and cerebrovascular diseases, in whom a sharp decrease in blood pressure can lead to myocardial infarction, stroke or impaired renal function, as well as in patients with cirrhosis of the liver.

Active ingredient

Vinpocetine, Indapamide, Metoprolol, Enalapril

Composition

1 tablet contains vinpocetine 2.5 mg,

Contraindications

Vinpocetine:
– hypersensitivity to vinpocetine;
– acute phase of hemorrhagic stroke, severe ischemic heart disease, severe cardiac arrhythmias;
— pregnancy, breastfeeding period;
— age up to 18 years.
Metoprolol:
– hypersensitivity to metoprolol;
— cardiogenic shock;
— AV blockade II and III degrees (without artificial pacemaker);
– sinoatrial blockade, sick sinus syndrome, severe bradycardia (heart rate less than 50 beats/min), severe peripheral circulatory disorders, heart failure in the stage of decompensation;
– bronchial hyperreactivity (for example, in severe bronchial asthma in patients receiving continuous or intermittent therapy with inotropic drugs acting on beta-adrenergic receptors, COPD in the acute stage);
– Prinzmetal’s angina;
– arterial hypotension (in case of use for secondary prevention of myocardial infarction – systolic blood pressure less than 100 mm Hg);
– if acute myocardial infarction is suspected (heart rate less than 45 beats/min, PQ interval more than 0.24 seconds or systolic blood pressure less than 100 mm Hg);
— pheochromocytoma (without simultaneous use of alpha-blockers);
—simultaneous use of monoamine oxidase inhibitors (MAO);
– period of breastfeeding;
— age up to 18 years (efficacy and safety have not been established).
Indapamide:
– hypersensitivity to indapamide and other sulfonamide derivatives;
– severe renal impairment (creatinine clearance less than 30 ml/min) and/or liver (including encephalopathy);
— hypokalemia;
— pregnancy, breastfeeding period;
— age up to 18 years.
Enalapril:
– hypersensitivity to enalapril and other ACE inhibitors;
– history of angioedema (Quincke’s edema) associated with taking an ACE inhibitor;
— hereditary/idiopathic angioedema;
– simultaneous use with aliskiren;
— pregnancy, breastfeeding period;
— age up to 18 years (efficacy and safety have not been established).
Hypotef:
– hypersensitivity to the excipients included in the drug;
– lactose intolerance, lactase deficiency and glucose-galactose malabsorption syndrome;
– use in patients under 45 (efficacy and safety have not been established).
With caution
Vinpocetine:
When used simultaneously with other antihypertensive drugs or drugs that prolong the QT interval, impaired liver function, poor tolerance to Vinca minor alkaloids.
Indapamide:
Diabetes mellitus, hyperuricemia (especially accompanied by gout and urate nephrolithiasis), hyponatremia and other water-electrolyte imbalances, moderate hepatic and/or renal failure, ascites, ischemic heart disease, chronic heart failure, concomitant use of drugs that prolong the QT interval, hyperparathyroidism, in weakened patients with an increased QT interval on the ECG or receiving combined therapy with other antiarrhythmic drugs.
Metoprolol:
Diabetes mellitus, metabolic acidosis, impaired liver and/or renal function (creatinine clearance less than 40 ml/min), myasthenia gravis, 1st degree AV block, thyrotoxicosis, depression (including history), psoriasis, history of allergic reactions (possible increased sensitivity to allergens, worsening arterial hypertension and decreased therapeutic response to adrenaline), bronchial asthma, COPD, pulmonary emphysema, chronic obstructive bronchitis, obliterating peripheral vascular diseases (intermittent claudication, Raynaud’s syndrome), old age (over 60 years).
Enalapril:
Systemic connective tissue diseases (including systemic lupus erythematosus, scleroderma), immunosuppressant therapy (risk of developing neutropenia, agranulocytosis), inhibition of bone marrow hematopoiesis, reduced circulating blood volume (taking diuretics, salt-free diet, vomiting, diarrhea), coronary heart disease, cerebrovascular diseases, renovascular hypertension, diabetes diabetes, chronic heart failure (functional class IV according to the NYHA classification), old age (over 60 years); hemodialysis using high-flux membranes (for example, AN69®) or desensitization, low-density lipoprotein (LDL) apheresis, renal artery stenosis (including bilateral), condition after kidney transplantation; Aortic valve stenosis/hypertrophic cardiomyopathy, hyperkalemia.

Side Effects

Adverse reactions are divided according to the following frequency: very often – more than 1/10, often – more than 1/10, less than 1/10; uncommon – more than 1/1000, less than 1/100; rarely – more than 1/10000, less than 1/1000; very rarely – less than 1/10000; unspecified frequency (cannot be calculated from available data).

Interaction

Vinpocetine

Overdose

Vinpocetine

Storage conditions

In a dry place, protected from light, at a temperature not exceeding 25°C.

Shelf life

2 years.

Manufacturer

Sintez, Russia